Urogen Pharma (NASDAQ:URGN) Posts Earnings Results

Urogen Pharma (NASDAQ:URGN) released its quarterly earnings data on Wednesday. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02), FiscalAI reports. The business had revenue of $72.46 million for the quarter, compared to analysts’ expectations of $63.55 million.

Here are the key takeaways from Urogen Pharma’s conference call:

• ZUSDURI revenue reached $50.4 million in Q2, up 73% sequentially, with 1,444 activated accounts, 452 prescribers, and repeat prescribers representing approximately 45% of writers. Community practices accounted for about 55% of utilization, supporting the company’s view that adoption remains in an early growth phase.
• UroGen reported durable ZUSDURI clinical results, with 64.5% of complete responders estimated to remain disease-free at 36 months and median response duration not yet reached. Management said real-world physician experience is increasingly supporting use beyond patients who are poor surgical candidates.
• JELMYTO revenue was stable at $22 million, and the company maintained its 2026 guidance of $97 million to $101 million. However, management has not yet observed a meaningful “reverse halo” effect from the ZUSDURI launch on JELMYTO demand.
• UroGen expects to submit the UGN-103 NDA within weeks, complete UGN-104 enrollment by year-end, and begin a UGN-501 Phase I study later in 2026. A patent allowance covering ZUSDURI and UGN-103 is expected to provide protection through July 2044.
• Full-year operating expense guidance increased to $260 million-$270 million as UroGen accelerates ZUSDURI promotional and patient-awareness spending and advances pipeline programs. Management remains confident it can reach profitability with existing capital resources, but the higher investment is expected to pressure near-term results.

Urogen Pharma Stock Up 16.4%

Urogen Pharma stock traded up $6.54 during midday trading on Wednesday, hitting $46.45. 2,147,129 shares of the stock were exchanged, compared to its average volume of 793,060. Urogen Pharma has a 52-week low of $15.86 and a 52-week high of $47.84. The business’s 50-day moving average price is $35.39 and its 200-day moving average price is $26.61. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of -16.80 and a beta of 1.57.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. HC Wainwright reissued a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Friday, July 17th. UBS Group restated a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. Finally, Oppenheimer lifted their target price on Urogen Pharma from $40.00 to $50.00 and gave the company an “outperform” rating in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $41.62.

Insider Activity at Urogen Pharma

In other news, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the transaction, the insider owned 119,763 shares in the company, valued at $4,790,520. The trade was a 7.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 25,222 shares of company stock worth $892,661. 4.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Urogen Pharma

Large investors have recently made changes to their positions in the business. Invesco Ltd. raised its position in Urogen Pharma by 21.1% in the fourth quarter. Invesco Ltd. now owns 27,066 shares of the company’s stock worth $634,000 after acquiring an additional 4,711 shares during the period. Susquehanna Portfolio Strategies LLC bought a new position in shares of Urogen Pharma during the 4th quarter valued at approximately $641,000. Superstring Capital Management LP increased its stake in shares of Urogen Pharma by 717.1% during the 4th quarter. Superstring Capital Management LP now owns 718,354 shares of the company’s stock worth $16,824,000 after purchasing an additional 630,442 shares during the last quarter. Orbimed Advisors LLC increased its stake in shares of Urogen Pharma by 27.1% during the 4th quarter. Orbimed Advisors LLC now owns 875,487 shares of the company’s stock worth $20,504,000 after purchasing an additional 186,487 shares during the last quarter. Finally, Opaleye Management Inc. bought a new stake in shares of Urogen Pharma in the 4th quarter worth approximately $6,286,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.